Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Touts Endeavor Safety Results; Are Late Lumen Loss Issues Over?

This article was originally published in The Gray Sheet

Executive Summary

Medtronic is stressing the deliverability of its Endeavor drug-eluting stent and safety results from the ENDEAVOR-II trial to distinguish the device from competitors, but concerns with late lumen loss remain
Advertisement

Related Content

EuroPCR In Brief
Panel Advises 5,000-Patient Postmarket Study For Medtronic’s DES
Medtronic Misses Endeavor Primary Endpoint, But Claims PMA Still On Track
Medtronic Spotlights Endeavor Stent Launch Abroad, ICDs Domestically
Medtronic Endeavors To Gain Drug-Eluting Stent Share In Europe
Angiographic Surrogates Gaining Importance For DES Trials – CDRH’s Boam
Medtronic Gears For Stent Patent Infringement Showdowns With J&J, Guidant
Boston Scientific, J&J Dwell In Separate REALITY; Data Swamps ACC
Taxus Will Continue To Lead Coronary Stent Market, Boston Scientific Vows
Taxus Will Continue To Lead Coronary Stent Market, Boston Scientific Vows
Advertisement
UsernamePublicRestriction

Register

MT021775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel